Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma

Arthritis and Rheumatism

Volumn 39, Issue 7, 1996, Pages 1146-1150

  Stein, C Michael ^a,b   Tanner, S Bobo ^a   Awad, Joseph A ^a   Roberts II, L Jackson ^a   Morrow, Jason D ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN F2; PROSTAGLANDIN SYNTHASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; SCLERODERMA;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSTAGLANDINS F, SYNTHETIC; SCLERODERMA, SYSTEMIC; THROMBOXANE B2;

EID: 0029946665     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390711     Document Type: Article

References (29)

1. Murrell DF: A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78-85, 1993
2. Murrell GAC, Francis MJO, Bromley L: Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 265:659-665, 1990
3. Del Maestro RF, Thaw HH, Bjork J, Planker M, Arfors KE: Free radicals as mediators of tissue injury. Acta Physiol Scand 492:43-57, 1980
4. Silverstein JL, Steen VD, Medsger TA, Falanga V: Cutaneous hypoxia in patients with scleroderma. Arch Dermatol 128:1379-1382, 1988
5. Roberts LJ, Morrow JD: Isoprostanes: novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury. Ann N Y Acad Sci 744:233-242, 1993
6. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proc Natl Acad Sci U S A 87:9383-9387, 1990
7. 2α, is formed in vivo. Biochim Biophys Acta 1210:244-248, 1994
8. Morrow JD, Harris TM, Roberts LJ: Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem 184:1-10, 1990
9. 2-isoprostanes) in smokers. N Engl J Med 332:1198-1203, 1995
10. 2-isoprostanes) in carbon tetrachloride hepatotoxicity: an animal model of lipid peroxidation. J Clin Invest 90:2502-2507, 1992
11. 2 isoprostanes) in the hepatorenal syndrome. J Lipid Mediat 6:417-420, 1993
12. 2-isoprostane) metabolites in human plasma and urine. J Biol Chem 268:4161-4169, 1993
13. Reilly IAG, Roy L, Fitzgerald GA: Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. BMJ 292:1037-1039, 1986
14. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590, 1980
15. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205, 1988
16. 2 by gas chromatography-mass spectrometry. J Chromatogr 612:179-185, 1993
17. Suryaprabha P, Das UN, Ramesh G, Kumar KV, Kumar GS: Reactive oxygen species, lipid peroxides and essential fatty acids in patients with rheumatoid arthritis and systemic lupus erythematosus. Prostaglandins Leukot Essent Fatty Acids 43:251-255, 1991
18. Halliwell B: Free radicals, antioxidants and human disease: curiosity, cause or consequence. Lancet 344:721-724, 1994
19. Doelman CJA, Bast A: Oxygen radicals in lung pathology. Free Radic Biol Med 9 (suppl 1):381-400, 1990
20. Rodnan GP, Myerowitz RL, Justh GO: Morphologic changes in digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine (Baltimore) 59:393-408, 1980
21. Gurtner GH, Burke-Wolin T: Interactions of oxidant stress and vascular reactivity. Am J Physiol 260:L207-L211, 1991
22. Marczin N, Ryan US, Catravas JD: Methylene blue inhibits nitrovasodilator and endothelium derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. J Pharmacol Exp Ther 263:170-179, 1992
23. Lau CS, Bridges AB, Muir A, Scott N, Bancroft A, Belch JJ: Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br J Rheumatol 31:375-380, 1992
24. Gutteridge JMC, Halliwell B: The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 15:129-135, 1990
25. Halliwell B, Grootveld M: The measurement of free radical reactions in humans; some thoughts for future experimentation. FEBS Lett 213:9-14, 1987
26. 2 synthesis. J Biol Chem 264:141-150, 1989
27. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM: Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 38:1060-1067, 1995
28. 2α in rabbit lung in situ. Am J Physiol 263:H660-H663, 1992
29. Stein CM, Longmire AW, Minton TA, Roberts LJ, Pincus T, Morrow JD: Cyclosporine-induced alterations in renal function are not associated with lipid peroxidation. Transplantation 58: 386-388, 1994